Melanotan-2 and pigment changes
An unapproved pigment-stimulating peptide whose visible effects need to be considered alongside uncertain long-term safety and reports of serious harm.
Pigment is a biological response
Melanotan-2, also called melanotan II, is a synthetic cyclic peptide related to alpha-MSH, a hormone involved in pigment signaling. It acts at several melanocortin receptors. Receptors are proteins through which cells respond to chemical signals. Those pathways extend beyond skin, which helps explain why the literature also includes appetite and sexual-function experiments.
The history of melanocortin therapeutics describes the wider development of this family. Related substances are not interchangeable. An approval for a different melanocortin medicine does not establish an approved use for melanotan-2.
Pigment production is not the same outcome as improved skin structure or fewer fine lines. A deeper color cannot establish healthier skin, and the appearance of a tan does not resolve the safety questions about the substance producing it.
A case with follow-up after stopping
A 2026 oral-pigmentation case report describes a man who developed brown pigmentation on his gums and inside his cheeks after self-administering melanotan II. The cheek pigmentation began fading by 28 days after he stopped. At three months, lighter gum pigmentation remained.
This is one person's clinical record. It documents the sequence of exposure, observation, and follow-up, but cannot predict how another person will respond. It also provides no estimate of how often oral pigmentation occurs among people exposed to the compound.
The different courses in the gums and cheeks matter. The end of exposure did not coincide with the disappearance of every visible change. Words such as temporary or reversible need follow-up measurements rather than an assumption that pigment ends when exposure ends.
What small experiments establish
A 1998 double-blind crossover study examined erectile responses in ten men with psychogenic erectile dysfunction. The investigators reported erections and transient effects including nausea, stretching, and yawning. The small, specific population and the study's purpose limit what it can establish about cosmetic exposure.
A 2022 experiment in male mice delivered melanotan II directly into a brain region involved in motivation. Food intake and work to obtain food fell. That route and species are central to interpreting the result. It does not establish an appetite treatment or a long-term safety profile in people.
Neither experiment supplies the missing evidence about repeated tanning use. A biological response can be measurable without establishing that a proposed use is appropriate or safe.
Safety concerns
A kidney-injury case report and literature review describes renal infarction, an interruption of blood supply to kidney tissue, considered possibly related to melanotan II. The authors discuss possible clotting and toxic mechanisms. A case report can identify a serious concern without proving causation or establishing its frequency.
The broader case literature includes prolonged erections, changes in moles, and melanoma reported in users. These reports do not establish a causal melanoma risk estimate. They also do not justify dismissing a new or changing mole as an expected cosmetic effect. A prolonged painful erection requires emergency medical assessment; changing moles warrant evaluation by a qualified health professional.
The FDA's safety-risk page, current as of April 22, 2026, lists melanotan II as nominated but withdrawn. Withdrawal is not clearance or approval. Melanotan-2 has no FDA-approved use, and the page retains its safety concerns beside the entry.
Reports are not risk estimates
People in peptide-use communities describe darker freckles or moles, uneven color, patchy fading, nausea, flushing, fatigue, and changes in appetite or sexual response. These accounts are anecdotal, not clinical evidence. Their frequency in a discussion does not show how commonly an effect occurs across all exposed people.
There is no validated human pharmacokinetic half-life established for melanotan II itself in the source material discussed here. A half-life describes how long a measured amount takes to fall by half. It is a different measurement from the duration of pigment in skin or the mouth.
This page provides no use schedule or dosing instructions. The comparison keeps pigment follow-up separate from copper transport and hair outcomes, while the source descriptions show what each kind of evidence contributes.